You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 5, 2024

Details for Patent: 8,546,428


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 8,546,428 protect, and when does it expire?

Patent 8,546,428 protects SIRTURO and is included in one NDA.

This patent has forty patent family members in thirty-three countries.

Summary for Patent: 8,546,428
Title:Fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-- beta-phenyl-3-quinolineethanol
Abstract: The present invention relates to the fumarate salt of (alpha S, beta R)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-- beta-phenyl-3-quinolineethanol, pharmaceutical compositions comprising as active ingredient said salt and to processes for their preparation.
Inventor(s): Hegyi; Jean Francois Alexandre Lucas (Diest, BE), Aelterman; Wim Albert Alex (Gierle, BE), Lang; Yolande Lydia (Vosselaar, BE), Stokbroekx; Sigrid Carl Maria (Beerse, BE), Leys; Carina (Stabroek, BE), Van Remoortere; Peter Jozef Maria (Kapellen, BE), Faure; Anne (Vosselaar, BE)
Assignee: Janssen Pharmaceutica NV (Beerse, BE)
Application Number:12/515,986
Patent Claim Types:
see list of patent claims
Composition; Compound; Dosage form; Process; Formulation; Use;

Drugs Protected by US Patent 8,546,428

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-002 May 27, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS ⤷  Sign Up
Janssen Therap SIRTURO bedaquiline fumarate TABLET;ORAL 204384-001 Dec 28, 2012 RX Yes Yes ⤷  Sign Up ⤷  Sign Up Y Y TREATMENT OF PULMONARY MULTI-DRUG RESISTANT TUBERCULOSIS ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 8,546,428

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
06125443Dec 5, 2006
PCT Information
PCT FiledDecember 03, 2007PCT Application Number:PCT/EP2007/063186
PCT Publication Date:June 12, 2008PCT Publication Number: WO2008/068231

International Family Members for US Patent 8,546,428

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 2498 ⤷  Sign Up
Argentina 064149 ⤷  Sign Up
Australia 2007328945 ⤷  Sign Up
Brazil PI0719693 ⤷  Sign Up
Canada 2668512 ⤷  Sign Up
Chile 2007003472 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.